Clinical Trial: Dendritic Cell Immunotherapy for Treatment of Adult GBM

U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT06805305) titled 'Dendritic Cell Immunotherapy for Treatment of Adult GBM' on Jan. 14.

Brief Summary: The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone.

Participants in the DOC1021 + pIFN + SOC arm will:

* Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection

* Undergo ultrasound guided perinodal DOC1021 injections ever...